This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wapnir, I. L. Articles by Wolmark, N. Search for Related Content PubMed PubMed Citation Articles by Wapnir, I. L. Articles by Wolmark, N.

Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Five National Surgical Adjuvant Breast and Bowel Project Node-Positive Adjuvant Breast Cancer Trials

Irene L. Wapnir, Stewart J. Anderson, Eleftherios P. Mamounas, Charles E. Geyer, Jr, Jong-Hyeon Jeong, Elizabeth Tan-Chiu, Bernard Fisher, Norman Wolmark

From the National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center; Department of Biostatistics, University of Pittsburgh Graduate School of Public Health; Allegheny General Hospital, Pittsburgh, PA; Stanford University School of Medicine, Stanford, CA; Aultman Cancer Center and Northeastern Ohio Universities College of Medicine, Canton, OH; and Cancer Research Network, Plantation, FL.

Address reprint requests to Irene L. Wapnir, MD, Stanford University School of Medicine, 300 Pasteur Dr H-3625, Stanford, CA 94305-5655; e-mail: wapnir{at}stanford.edu

PURPOSE: Locoregional failure after breast-conserving surgery is associated with increased risk of distant disease and death. The magnitude of this risk in patients receiving chemotherapy has not been adequately characterized.

PATIENTS AND METHODS: Our study population included 2,669 women randomly assigned onto five National Surgical Adjuvant Breast and Bowel Project node-positive protocols (B-15, B-16, B-18, B-22, and B-25), who were treated with lumpectomy, whole-breast irradiation, and adjuvant systemic therapy. Cumulative incidences of ipsilateral breast tumor recurrence (IBTR) and other locoregional recurrence (oLRR) were calculated. Kaplan-Meier curves were used to estimate distant–disease-free survival (DDFS) and overall survival (OS) after IBTR or oLRR. Cox models were used to model survival using clinical and pathologic factors jointly with IBTR or oLRR as time-varying predictors.

RESULTS: Four hundred twenty-four patients (15.9%) experienced locoregional failure; 259 (9.7%) experienced IBTR, and 165 (6.2%) experienced oLRR. The 10-year cumulative incidence of IBTR and oLRR was 8.7% and 6.0%, respectively. Most locoregional failures occurred within 5 years (62.2% for IBTR and 80.6% for oLRR). Age, tumor size, and estrogen receptor status were significantly associated with IBTR. Nodal status and estrogen and progesterone receptor status were significantly associated with oLRR. The 5-year DDFS rates after IBTR and oLRR were 51.4% and 18.8%, respectively. The 5-year OS rates after IBTR and oLRR were 59.9% and 24.1%, respectively. Hazard ratios for mortality associated with IBTR and oLRR were 2.58 (95% CI, 2.11 to 3.15) and 5.85 (95% CI, 4.80 to 7.13), respectively.

CONCLUSION: Node-positive breast cancer patients who developed IBTR or oLRR had significantly poorer prognoses than patients who did not experience these events.

Supported by Public Health Service Grant Nos. U10-CA-12027, CA-69651, CA-37377, and CA-69974 from the National Cancer Institute, Department of Health and Human Services.

Presented in part at the 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, May 20-23, 2000.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				P. L. Nguyen, A. G. Taghian, M. S. Katz, A. Niemierko, R. F. Abi Raad, W. L. Boon, J. R. Bellon, J. S. Wong, B. L. Smith, and J. R. Harris Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated With Local and Distant Recurrence After Breast-Conserving Therapy J. Clin. Oncol., May 10, 2008; 26(14): 2373 - 2378. [Abstract] [Full Text] [PDF]

				K. L. Kahn Moving Research From Bench to Bedside to Community: There Is Still More to Do J. Clin. Oncol., February 1, 2008; 26(4): 523 - 526. [Full Text] [PDF]

				M. Morrow Magnetic Resonance Imaging in the Breast Cancer Patient: Curb Your Enthusiasm J. Clin. Oncol., January 20, 2008; 26(3): 352 - 353. [Full Text] [PDF]

				M. Morrogh, P. I. Borgen, and T. A. King The Importance of Local Control in Early-Stage Breast Cancer: A Historical Review and a Discussion of Ongoing Issues Ann. Surg. Oncol., December 1, 2007; 14(12): 3310 - 3320. [Full Text] [PDF]

				T. L. Lash, M. P. Fox, D. S.M. Buist, F. Wei, T. S. Field, F. J. Frost, A. M. Geiger, V. P. Quinn, M. U. Yood, and R. A. Silliman Mammography Surveillance and Mortality in Older Breast Cancer Survivors J. Clin. Oncol., July 20, 2007; 25(21): 3001 - 3006. [Abstract] [Full Text] [PDF]

				J. Mandelblatt To Screen or Not to Screen Older Women for Breast Cancer: A New Twist on an Old Question or Will We Ever Invest in Getting the Answers? J. Clin. Oncol., July 20, 2007; 25(21): 2991 - 2992. [Full Text] [PDF]

				M. R Kell and J. P Burke Management of breast cancer in women with BRCA gene mutation BMJ, March 3, 2007; 334(7591): 437 - 438. [Full Text] [PDF]

				O Gentilini, E Botteri, N Rotmensz, B Santillo, N Peradze, R. Saihum, M Intra, A Luini, V Galimberti, A Goldhirsch, et al. When can a second conservative approach be considered for ipsilateral breast tumour recurrence? Ann. Onc., March 1, 2007; 18(3): 468 - 472. [Abstract] [Full Text] [PDF]